Johnson Controls International PLC (JCI) Stock Price Today
Aura AI Summary
Key Stats
- $87.42BMarket Cap
- -Volume
- IndustrialsSector
- $148.2152W High
- $103.2452W Low
- -Typical Hold Time
- $96.25BEnterprise Value
- 1.12%Div Yield
- -Trading Activity
Track Johnson Controls International PLC (JCI) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Johnson Controls International PLC has traded between a low of $103.24 and a high of $148.21, highlighting its annual price range. Buy and sell Johnson Controls International PLC shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Most Recent News
Class action lawsuit filed against PROCEPT BioRobotics over alleged misleading sales and inventory practices.
Robbins Geller Rudman & Dowd LLP has filed a class action lawsuit against PROCEPT BioRobotics Corporation and its executives, accusing them of misleading investors by inflating sales figures through an undisclosed discount program that caused excess ...

Stocks surge as AI data center plans, IPO debut, and strong earnings drive big gains today
Stocks of several companies jumped significantly today due to key corporate developments. STAK Inc. led with a 596% rise after announcing a U.S. subsidiary to develop power systems for AI data centers, highlighting investor interest in AI infrastruct...

Stocks of Faraday Future and Zevra Therapeutics plunge amid regulatory and investor concerns.
Faraday Future Intelligent Electric Inc. saw its stock drop nearly 40% despite recent product showcases, indicating investor worries beyond its new offerings. Zevra Therapeutics' shares fell almost 24% after the European Medicines Agency issued a neg...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.